Table 4.

Trials of poly (ADP-ribose) polymerase (PARP) inhibitors [16].

Trials Focused Primarily in Breast Cancer with Brca Mutation
Study Name/NCT Identifier	Drug(s)/Novel Agent(s)	Study Phase	N	Primary Endpoint	Disease Setting
EMBRACA Study NCT01945775	Talazoparib vs. Physician’s Choice	III	429	PFS	Metastatic breast cancer patients with BRCA mutation
2014-0045 NCT02282345	Talazoparib	II	20	Toxicity, safety	Neoadjuvant, +BRCA mutation
Trials in Breast (with or without BRCA Mutation) and other Malignancies
Study Name/NCT Identifier	Drug(s)/Novel Agent(s)	Study Phase	N	Primary Endpoint	Disease Setting
OlympiA NCT02032823	Olaparib	III	1320	DFS	Adjuvant, TNBC in high risk BRCA 1/2
ComPAKT NCT02338622	Olaparib + AKT inhibitor (AZD5363)	I	58	Safety, tolerability	Advanced solid tumors, BRCA 1/2 mutation, TNBC or hyperactive PI3K-AKT pathway

Abbreviations: NCT = National Clinical Trials, DFS = disease free survival; N = number of patients; PFS = progression free survival; TNBC = triple negative breast cancer, AKT = abbreviation for proto-oncogene also known as protein kinase B or PKB, PI3K-AKT = phosphoinositide 3-kinase/AKT signaling pathway PI3K.